Cencora, Inc. (NYSE: COR) — The Toll Road on the Drug Supply Chain, Now Paving Side Roads Into Physician Practices

Report date: June 12, 2026 Price reference: ~$281.5 (NYSE close, 2026-06-11) | Market cap: ~$54.8B | EV: ~$62–68B | Shares: ~194.5M | FY-end: September 30

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice. The analysis that follows takes no position and carries no price target; it discusses valuation only as embedded expectations and scenarios.

Verdict: HOLD — quality oligopolist at a fair-to-slightly-cheap price; accumulate on weakness below ~$265–270. Conviction: medium. The directional zone I’d anchor to is ~15–16x mid-cycle adjusted EPS of ~$18–19, i.e. a fair band of roughly $280–$320, with genuine value emerging in the mid-$240s–$265 (where the stock found its 52-week low) and froth above ~$340.

Cencora is one of three toll-takers (with McKesson and Cardinal Health) on a structurally protected, recession-proof, ~$500B+ flow of US pharmaceuticals — a textbook Greenwald economies-of-scale + customer-captivity moat where the sub-1% operating margin is the barrier to entry. It has compounded adjusted EPS ~14.7%/yr (FY21 $9.26 → FY25 $16.00) on negative working capital, ~0.2%-of-sales capex, and a steady buyback. The ~25% drawdown from the $377 high is the market over-reacting to a revenue-guidance cut (7–9% → 4–6%) that is largely margin-neutral optics — slower GLP-1s, faster brand→biosimilar conversion at a big mail-order customer, and IRA list-price deflation all hit the pass-through revenue line, not the gross-profit dollars management actually steers by. At ~15.8x forward earnings and a ~5.7% FCF yield, the tape is underwriting only ~6–8% through-cycle EPS growth against a 10–14% algorithm — the cheapest of the Big-3, and the discount to McKesson is wider than COR’s modestly lower quality warrants.

So why only HOLD, and why the framing is “quality compounder with a fattening tail of self-inflicted risk” rather than a table-pounding long? Three things keep me honest. (1) Customer concentration is extreme and dated: Walgreens+Boots ≈ 25% of revenue and ~38% of receivables, now owned by Sycamore Partners (PE, since Aug-2025), with the anchor contracts up for renewal in 2029 — a single renegotiation is the largest idiosyncratic risk in the franchise. (2) The MSO pivot is a real strategic departure at the wrong point in the capital cycle: management is rolling up oncology/retina/ophthalmology physician practices (RCA, OneOncology at a 19x EBITDA put strike, EyeSouth) at prices PE already inflated, funding it with a doubling of net debt (~0.6x → ~1.9x) and carrying ~$1.8B of hidden physician put/earn-out claims — and it has already fully written off its last big non-distribution bet (PharmaLex, $1.14B impaired within ~2 years). (3) The bear case is a double-compression (EPS and multiple), so while the skew is asymmetric to the upside from spot, the left tail is real. The single fact that would flip me bullish: a Walgreens contract renewal on confirmed-stable economics through the mid-2030s. The single fact that would flip me bearish: evidence biosimilar disintermediation is leaking into the high-margin Part B specialty channel (not just Part D mail), or a third consecutive year of MSO/acquisition impairment.

1. Executive Summary

Cencora, Inc. (NYSE: COR) — known as AmerisourceBergen until its August-2023 rebrand — is the second-largest of the three US pharmaceutical distributors that together intermediate north of 90% of the prescription drugs sold in America. In FY2025 (ended September 30, 2025) it moved $321.3 billion of revenue at a 3.57% gross margin and a ~0.8% GAAP operating margin, generating ~$3.9B of operating cash flow on just ~$668M of capex. This is a high-volume, razor-thin, capital-light logistics utility: the company keeps roughly three-and-a-half cents of gross profit and under one cent of operating profit per revenue dollar, and the investable signal is gross-profit-dollar growth and mix, not the headline revenue number.

The business earns its keep through an economies-of-scale plus customer-captivity moat in the truest Greenwald sense — the sub-1% margin is simultaneously the source of low returns on sales and the deterrent that keeps new entrants out, because no one can profitably replicate a national, highly-automated, auto-replenishment distribution network to skim a fraction of a percent. Returns on capital (not sales) are high — ROIC comfortably in the ~12–22% range depending on method, against a ~7–9% WACC — and the three-firm share structure (MCK ~35% / COR ~30% / CAH ~25%) has been stable for over a decade. Adjusted diluted EPS has compounded ~14.7% per year from $9.26 (FY21) to $16.00 (FY25), powered by specialty mix, a generics-sourcing scale advantage, negative working capital, and consistent share repurchase.

Three forces define the forward debate. First, the revenue air-pocket: at Q2 FY2026 (reported May 6, 2026) management cut FY2026 revenue guidance from +7–9% to +4–6% — but raised operating-income guidance to +12–14% and nudged adjusted EPS to $17.65–$17.90. The revenue cut reflects slower GLP-1 growth, faster-than-expected brand→biosimilar conversion at a large mail-order customer, and IRA-driven manufacturer list-price (WAC) reductions — all of which compress the low-margin pass-through revenue line far more than the profit pool. The market treated this as a growth scare and took the stock down ~25% from its high; we read it as largely transitory and margin-neutral, though core operating-income growth did decelerate to ~7% (the low end of the long-term algorithm). Second, customer concentration: Walgreens+Boots is ~25% of revenue with anchor contracts expiring in 2029, now under PE ownership (Sycamore) — the largest single risk to the franchise. Third, the MSO roll-up: Cencora is using its distribution cash flows to acquire majority stakes in physician-practice management companies (RCA in retina, OneOncology in oncology, EyeSouth in ophthalmology), a margin-accretive but capital-intensive, top-of-cycle diversification that has doubled leverage and added ~$1.8B of contingent physician-put liabilities.

At ~15.8x forward adjusted EPS and ~12.4x EV/EBITDA, Cencora is the cheapest of the Big-3 — a discount that is partly rational (lower ROIC than McKesson, higher leverage, the Walgreens overhang, a $4.3B opioid liability) and partly an over-reaction to a revenue cut investors mis-read as a profit cut. This memo takes no position and sets no target; the analysis below frames what the price is underwriting and where the thesis breaks on each side.

2. Business Overview

What Cencora does

Cencora sits in the middle of the pharmaceutical supply chain. Manufacturers (Pfizer, Lilly, Novo, Amgen, the generics houses) sell to Cencora; Cencora warehouses, breaks bulk, and delivers — often on a next-day, auto-replenishment basis — to the ~tens of thousands of points of care that dispense or administer drugs: retail pharmacy chains, independent pharmacies, mail-order/PBM pharmacies, hospitals and health systems, physician practices (especially oncology and other specialties), long-term-care and alternate-site pharmacies, and clinics. It is, in management’s own framing, “the backbone of the pharmaceutical supply chain.”

The economic engine is not a simple cost-plus markup. It has two distinct profit mechanics:

• Brand drugs are largely distributed under fee-for-service distribution-service agreements (DSAs) with manufacturers — Cencora is paid a (largely fixed-percentage-of-WAC) fee for the logistics and data services it provides, partially decoupling its economics from drug list prices. This is the key reason management guides on operating income, not revenue: when a manufacturer cuts a list price (as the IRA increasingly forces), revenue falls but the fee can be renegotiated to preserve dollar profit.
• Generics are distributed on a buy-and-hold basis, where Cencora captures buy-side sourcing margin and manufacturer rebates. Generic sourcing scale is a genuine competitive variable; Cencora runs a global generics-sourcing operation, including an Ireland-based private-label program and — critically — a generics-purchasing-services arrangement with WBAD (Walgreens Boots Alliance Development GmbH), under which WBAD negotiates generic acquisition pricing on Cencora’s behalf (term to 2029).

Layered on top is a growing book of higher-margin specialty and value-added services: specialty distribution to oncology and other physician offices (Part B, physician-administered drugs), plasma and blood products, vaccines, cell and gene therapies; specialty logistics (World Courier); commercialization/consulting services to manufacturers (Innomar, the remnants of PharmaLex); the Good Neighbor Pharmacy and Elevate Provider Network programs that bind independent pharmacies; packaging; and, increasingly, physician-practice management services organizations (MSOs) in oncology, retina, and ophthalmology.

Segment structure and FY2025 economics

From Q1 FY2026 Cencora reorganized into three reporting units. On the FY2025 basis (10-K, ended 9/30/25):

Source: Cencora FY2025 10-K, MD&A segment tables and Note 13. Segment operating income ($4,223M) reconciles down to GAAP operating income of $2,628.6M after intangible amortization (-$553M), goodwill impairment (-$723.9M), deal/integration (-$291M), restructuring (-$229.4M), litigation/opioid (-$60.7M), Turkey hyperinflation (-$49.6M), offset by antitrust settlement gains (+$236.4M) and a LIFO credit (+$76.9M).

The single most important structural fact in this table: International is 9.5% of revenue but throws ~29% of segment gross profit and 15.4% of segment operating income, because its ~10.9% gross margin is roughly 4x the U.S. distribution segment’s 2.72%. The margin lives in services and specialty, not in moving boxes. U.S. Healthcare Solutions is the engine of dollars (it grew operating income +21.8% in FY25, aided by the January-2025 RCA acquisition); International (Alliance Healthcare European distribution + World Courier + Innomar) is the engine of rate.

A third bucket — “Other,” explicitly not a reportable segment — houses MWI Animal Health, Profarma (Brazil), the legacy U.S. consulting services business, and residual PharmaLex. This is the “for sale” shelf: MWI is being merged into Covetrus, the U.S. hub consulting business was divested April 30, 2026, and the very existence of this bucket signals a deliberate portfolio simplification toward U.S. specialty distribution + MSOs.

Customers, suppliers, and recurring-revenue character

Revenue is highly recurring and non-discretionary — drugs are repeat-purchase necessities, and Cencora is typically the primary or sole distributor to a given customer under auto-replenishment. But the concentration is severe and is the franchise’s defining idiosyncratic risk (covered in depth below): the top ten customers are ~66% of revenue, Walgreens + Boots ≈ 25%, and Evernorth (Cigna/Express Scripts) ≈ 13%. On the supply side, by contrast, there is healthy diversification — no single supplier exceeds 10% of purchases and the top ten are ~57%.

Verdict (Business Overview): A genuine utility-like, recession-resistant logistics franchise with deeply recurring volumes — but one whose reported revenue is a misleading pass-through gross number, whose profit pool is thin and mix-dependent, and whose customer base is dangerously concentrated in two payers/retailers. Read the gross-profit-dollar line and the specialty mix; ignore the $321B headline.

3. Industry Dynamics

Structure: a protected three-firm oligopoly

US pharmaceutical distribution is one of the cleanest oligopolies in large-cap America. Three firms — McKesson, Cencora, and Cardinal Health — intermediate 90%+ of the prescription drugs flowing from ~thousands of manufacturers to ~hundreds of thousands of dispensing/administering points. The structure has been remarkably stable for more than a decade: rough shares of MCK ~35% / COR ~30% / CAH ~25%, with the balance in regional and specialty players. This is not a market where share sloshes around; it is a mature, consolidated, share-stable system.

The industry’s defining feature — and the source of both its low margins and its high barriers — is bilateral scale economics on razor-thin spreads. Distributors add value by (a) consolidating thousands of manufacturer SKUs into single daily deliveries, (b) financing the channel’s working capital (they pay manufacturers and collect from customers on different cycles), © providing ordering technology, data, and regulatory/serialization compliance, and (d) sourcing generics at scale. The Healthcare Distribution Alliance estimates the channel adds ~$78–80B of annual value to the healthcare system at well under 1% of brand drug cost — the distributors capture only a sliver of the value they create, which is precisely why the system is hard to disrupt: there is very little margin to attack.

The economics are structurally attractive for incumbents in ways that don’t show up in the margin line:

• Negative working capital. Distributors collect from customers faster than they pay manufacturers, so growth is partly self-funding; the float is an enormous, low-cost financing source (Cencora’s net trade working capital is roughly -$9B).
• Trivial capex. At ~0.2% of sales, this is among the most capital-light “industrial” models in existence — incremental volume drops through at very high incremental returns on tangible capital.
• Volume tailwind. US prescription volume grows mid-single-digits structurally (aging demographics, chronic disease, specialty pipeline), and the specialty/biologic mix shift raises the dollar value per script even as unit growth moderates.

The threats — real but mostly second-order

The bear narrative on drug distribution has been “disruption is coming” for fifteen years, and it keeps not arriving — but the threats deserve specific treatment because some are now live:

1. IRA / list-price deflation. The Inflation Reduction Act’s Medicare price-negotiation and the broader manufacturer move to lower WAC list prices (e.g., insulin, and prospectively GLP-1s from 1/1/2027) cut the revenue line directly. To the extent distributor margin is a percentage of WAC, this is a margin headwind. The mitigant: most brand economics are fee-for-service DSAs that can be renegotiated to preserve dollar fees, and management states it has historically “recouped the value” of list-price changes. This is the single most important industry uncertainty — discussed further below.

2. Biosimilar disintermediation in Part D mail. As brands convert to biosimilars, mail-order pharmacies/PBMs can in-source the biosimilar and bypass the wholesaler — exactly as happened with oral generics. Management is explicit that this is already in the model (a revenue hit, not a meaningful profit hit, because mail brand sales are low-margin), and that the offsetting dynamic in Part B (physician-administered) specialty is actually beneficial to Cencora as brands convert to biosimilars in the channels where it has GPO and MSO presence. The risk the bears press: that disintermediation leaks from low-margin Part D mail into high-margin Part B specialty. No evidence of that yet, but it is the key thing to monitor.

3. Amazon Pharmacy / Mark Cuban Cost Plus / direct-to-patient. New retail-pharmacy and DTC models (including manufacturer-direct channels like Lilly Direct) reshuffle dispensing but still need physical drug logistics — and in several cases Amazon and others have partnered with, rather than replaced, the incumbent distributors. A genuine long-term watch item, not a near-term profit threat.

4. Payer/PBM in-sourcing. The most credible structural threat: a giant integrated payer (Evernorth/Cigna, CVS/Caremark, UnitedHealth/Optum) deciding to self-distribute. This is why Evernorth being simultaneously a ~13%-of-revenue customer and a potential disintermediator matters. To date the economics of self-distribution at sub-1% margin have not justified the capital, but it is the tail risk that would most damage the oligopoly.

Verdict (Industry): Structurally GOOD — for the incumbents. This is a consolidated, share-stable, recession-proof oligopoly with self-funding growth and trivial capital intensity, where the very thinness of the margin is the moat. It will never be a high-margin industry, and it carries real second-order disruption risks (IRA deflation, Part B biosimilar leakage, payer in-sourcing) — but as a place to deploy capital over a decade, the structure is attractive. In Marathon capital-cycle terms, core distribution is a low-supply-growth, high-barrier system; the caution is reserved for where the incumbents are now redeploying their cash (physician MSOs — see the capital-allocation discussion below).

4. Competitive Position

Naming the moat

In Greenwald’s taxonomy, Cencora’s core distribution moat is the strongest archetype: economies of scale reinforced by customer captivity, operating through a thin-margin cost structure that is itself the entry barrier.

• Economies of scale. Distribution is a dense fixed-cost network (automated DCs, fleet, IT, regulatory/serialization infrastructure, generic-sourcing volume). The Big-3 each spread these costs over hundreds of billions of throughput; a sub-scale entrant cannot match the unit cost on a fraction-of-a-percent margin. Generic sourcing in particular rewards the largest buyers.
• Customer captivity. Customers are bound by deep operational integration — auto-replenishment, ordering systems, inventory management, GPO contracts, and the simple fact that Cencora is often the sole supplier to a pharmacy or practice. Switching distributors is operationally disruptive for a low-margin pharmacy with no incentive to risk supply continuity to save basis points.
• The margin is the moat. This is the subtle point: because the incumbents capture so little of the value they create, there is almost no profit umbrella under which a disruptor could undercut them. You cannot win a price war to capture 0.8% operating margins.

The financial proof points hold up: ROIC well above WACC (the company’s adjusted ROIC is a long-term incentive metric and screens in the ~12–22% range depending on treatment of negative working capital and goodwill), a decade of share stability, and pricing power sufficient to “recoup the value” of list-price changes through DSA renegotiation. Morningstar and others assign a narrow moat; we agree the core is a real, durable advantage but not a wide one, because the customer captivity is offset by the customers’ own scale (the top customers are giant payers/retailers with bargaining power, as the periodic Walgreens contract renegotiations demonstrate).

COR vs. McKesson vs. Cardinal Health

Sources: company filings; public market-data feeds and consensus for MCK/CAH; figures approximate and for relative positioning only.

McKesson is the deserved premium name — higher ROIC, lower leverage, and a similarly strong specialty/oncology franchise (US Oncology Network). Cencora’s persistent ~2-turn P/E and ~3–5-turn EV/EBITDA discount to MCK is rational, not a free lunch: COR carries lower ROIC, higher (and recently doubled) leverage, the Walgreens ~25%-revenue concentration, a larger relative opioid liability, and the redeemable-NCI physician-put overhang. Cardinal Health, often pitched as “cheaper,” actually trades slightly richer than COR on forward earnings once you use its elevated FY26 EPS-growth guide — it is a higher-beta cyclical-recovery story, not a lower multiple. So among the three, COR is genuinely the cheapest, MCK the highest-quality, and CAH the most cyclical.

The MSO question — moat extension or capital-cycle trap?

The central competitive-position debate is not about core distribution; it is about where Cencora is taking the franchise next. Management is building Management Services Organizations that provide back-office, technology, contracting, and capital to physician practices in high-value Part B specialties — OneOncology (oncology, now fully owned), RCA / Retina Consultants of America (retina), and EyeSouth (ophthalmology, announced). The strategic logic is coherent and even defensive: these specialties are exactly where Cencora’s specialty distribution and GPO economics live, so owning the practice deepens customer captivity, locks in drug volume, and captures a higher-margin services fee on top of the distribution spread. As brands convert to biosimilars in Part B, the practice (and Cencora) benefits.

The skeptical read, through a Marathon capital-cycle lens, is harder to dismiss: Cencora is rolling up physician practices at the same time private equity has bid those assets to rich multiples — in several cases Cencora is effectively the PE seller’s exit. The OneOncology minority put was struck at 19x EBITDA. This is high-return capital (distribution cash flow) chasing assets at the expensive end of their own cycle, funded by a doubling of leverage and carrying contingent physician-put/earn-out claims of ~$1.8B that grow as the MSOs succeed. And the cautionary precedent is fresh: Cencora’s last large non-distribution diversification, PharmaLex (EU regulatory consulting, 2023), was 100% goodwill-impaired within ~2 years ($418M FY24 + $723.9M FY25 = $1.14B). The MSO bet may well work — early integration commentary (OneOncology + RCA sharing best practices) is encouraging — but it is a separate, higher-risk capital wager layered on top of the distribution moat, and the burden of proof sits with management.

Verdict (Competitive Position): DURABLE narrow moat in the core, unproven bet on the edge. The distribution franchise is a real, scale-and-captivity advantage that will persist. The MSO roll-up is strategically logical but is being executed at a hot point in the capital cycle with rising leverage and a recent impairment track record — it is the part of the competitive story most likely to destroy, rather than create, value.

5. Growth History and Forward Opportunities

The history: flat GAAP, compounding adjusted

The headline that confuses first-time readers: GAAP net income has been essentially flat — $1,540M (FY21), $1,699M (FY22), $1,745M (FY23), $1,509M (FY24), $1,554M (FY25) — while gross profit nearly doubled ($6,943M → $11,479M). The reconciliation (detailed below) is that the add-backs (opioid charges, intangible amortization from the acquisition spree, impairments, deal/restructuring costs) grew in lockstep with the business. On the metric management and the sell-side actually track, adjusted diluted EPS compounded ~14.7%/yr:

Adjusted EPS series per company earnings releases / MD&A; FY26 per Q2 FY26 guidance.

This growth has been high quality in its drivers even if the accounting is messy: it is driven by (a) the secular mid-single-digit rise in US prescription volume, (b) a continuous mix shift toward specialty (oncology, retina, plasma, cell & gene), which carries higher gross-profit dollars per unit, © generic-sourcing scale, (d) the negative-working-capital float financing growth, and (e) a steady buyback (~7.5% net share reduction FY22→FY25). The growth is partly acquired (Alliance, RCA, OneOncology) and partly organic; the organic specialty-volume growth is the highest-quality piece.

The FY2026 deceleration — what actually happened

At Q2 FY2026, management cut revenue guidance from +7–9% to +4–6%. The drivers, in their own words:

• Slower GLP-1 growth. GLP-1s still grew (+$1.9B YoY in the quarter) but below plan; given the size of the class, a 5-point growth delta is ~$2B of revenue. These are low-margin, so the revenue hit is concentrated, not a proportional profit hit.
• Faster-than-expected brand→biosimilar conversion at a large mail-order customer. Low-margin brand revenue moving out of the channel — again, revenue-heavy, profit-light, and in fact margin-accretive to the mix.
• IRA / WAC list-price reductions — ~$2B revenue headwind in the quarter, the deflation mechanic described in the industry section.
• Plus the lapping of a lost oncology customer (acquired July 2025) and a lost grocery customer, and transitory weather/COVID-vaccine items.

Crucially, management raised operating-income guidance to +12–14% and adjusted EPS to $17.65–$17.90, and reaffirmed the long-term algorithm of 7–10% organic operating-income growth + 3–4% from capital deployment = 10–14% adjusted EPS growth. The honest caveat: a portion of the EPS raise was an accounting benefit (MWI reclassified as held-for-sale, suspending depreciation), and core operating-income growth in the quarter, stripped of OneOncology and the lost oncology customer, was ~7% — the low end of the algorithm. So the deceleration is partly transitory (weather, COVID, comps) and partly a genuine moderation that bears flag.

Forward opportunities

• Specialty and Part B biosimilars. The richest vein: physician-administered specialty drugs and the biosimilar conversion wave in Part B, where Cencora’s GPO + MSO presence makes conversion accretive.
• MSO platform expansion. OneOncology, RCA, EyeSouth and future bolt-ons — if integration and physician retention hold, a higher-margin, higher-growth services layer (see the capital-allocation and risk discussion below).
• Cell & gene therapy / specialty logistics. World Courier and global specialty logistics are winning cell-and-gene and lab-logistics contracts; two consecutive quarters of operating-income growth after a rough patch.
• International distribution. Alliance Healthcare’s European footprint is growing high-single-digits constant-currency.
• Digital / AI productivity. Automation and AI-supported customer-service tooling as an opex-leverage story (incremental, not transformative).

Verdict (Growth): High-quality growth, decelerating at the margin. The adjusted-EPS compounding is real and durably-sourced (specialty mix + volume + buyback + float), and the FY26 revenue cut is mostly a low-margin pass-through optics problem. But core growth has moderated to the low end of the algorithm, and the forward growth increasingly depends on the MSO bet executing — a higher-risk, more capital-intensive engine than the distribution flywheel that produced the historical record.

6. Capital Allocation

Capital allocation is where the Cencora thesis is most genuinely two-sided. The distribution-side track record is excellent; the diversification-side discipline is now being stress-tested.

M&A scorecard

The PharmaLex write-off is the most important capital-allocation fact in the file: the entire goodwill of a major acquisition was impaired within roughly two years of closing, across two consecutive fiscal years. That is not a one-time accounting artifact; it is an admission of overpayment on a non-core diversification — and it is precisely the precedent that should temper enthusiasm for the much larger MSO roll-up. The MSO deals are more strategically defensible (they reinforce the core specialty franchise rather than wandering into EU consulting), but they are being struck at full prices (19x EBITDA on the OneOncology put) at a point when PE has inflated the asset class.

Hidden debt-like claims

Beyond reported debt, Cencora’s MSO structure creates ~$1.8B of contingent physician-put / earn-out claims (RCA equity units ~$694M, RCA earnout ~$393M, OneOncology ~$752M) — redeemable minority interests that are indexed to EBITDA multiples and therefore grow as the MSOs succeed. Combined with the $4.3B opioid settlement liability (~$416M/yr cash through ~FY2038), these are real claims on future cash flow that sit outside the headline net-debt figure and should be added to any honest enterprise-value calculation.

Leverage

Total debt rose from $7.66B (FY25) to ~$12.39B (Mar 2026) to fund OneOncology (new senior notes to 2056 + term loans); net debt ~$3.3B → ~$10.2B, and net-debt/adjusted-EBITDA ~0.6x → ~1.9x. This is still investment-grade and manageable, but it is a material change in the balance-sheet posture of a company that historically ran near-net-cash — and it is the direct reason the buyback was paused.

Shareholder returns

• Buybacks: $484M (FY22) → $1,181M (FY23) → $1,491M (FY24) → $435M (FY25, paused for M&A). Diluted shares fell ~7.5% (211.2M FY22 peak → 195.2M FY25). The company is resuming ~$1B of repurchase by end-CY2026 at ~$266–281, with ~$882M left on the $2B authorization. Timing critique: the heaviest buying came during the FY24 run-up, the pause coincided with the ~$377 peak, and the resumption is at lower prices — so the direction is right now, but the pause was cash-forced (M&A), not a deliberate valuation call. Mixed marks on buyback discipline.
• Dividend: ~$2.20–2.40/share, ~14% payout, ~0.9% yield — steadily growing within the EPS-growth algorithm but not a Dividend Aristocrat. A token return; this is a buyback-and-reinvest story, not an income story.

Incentive alignment — a genuine positive

The proxy is encouraging. Short-term incentive: 40% Adjusted Operating Income / 25% Adjusted EPS / 25% Adjusted Free Cash Flow / 10% other. Long-term PSUs: 75% Adjusted EPS CAGR + 25% Adjusted ROIC, with a TSR modifier. The presence of Adjusted ROIC and Adjusted FCF as explicit metrics is real capital discipline — exactly the gauges you want governing a serial acquirer. The caveat: everything is on an adjusted basis that adds back the impairments, deal costs, and amortization the M&A itself creates, so a PharmaLex-style write-off does not directly dent the pay metrics. Still, the metric set is better than most. CEO Bob Mauch’s FY25 total compensation was ~$18.3M.

Management transition

CFO Jim Cleary is retiring (last earnings call was Q2 FY26; departs the company December 2026). His successor, named via 8-K dated May 29, 2026, is Eva C. Boratto (effective June 29, 2026) — former CFO of Bath & Body Works and, notably, former CFO of CVS Health (2018–21), with 20 years at Merck and board seats at Mars and UPS. A seasoned healthcare-finance hire onto a relatively young leadership bench (CEO Mauch is only ~2 years into the role, having succeeded Steven Collis, now Executive Chairman).

Verdict (Capital Allocation): Good distribution-side allocator now testing its discipline in a hot MSO capital cycle. The buyback history, low historical leverage, growing dividend, and genuine ROIC/FCF pay metrics are all positives. Against them: a full PharmaLex write-off, a 19x EBITDA MSO multiple, a doubled debt load, ~$1.8B of hidden physician-put claims, and a buyback pause that was cash-forced rather than valuation-driven. Not empire-building — the strategy is coherent — but management is paying up at the expensive end of the cycle, and the next two years of MSO marks will tell us whether the PharmaLex impairment was an aberration or a pattern.

7. (Financial Quality) — Earnings Quality, Cash, and the Balance Sheet

The GAAP-vs-adjusted bridge

The defining quality-of-earnings issue is the wide and recurring wedge between GAAP and adjusted earnings. FY2025: GAAP diluted EPS $7.96 vs. adjusted $16.00 — a ~$8.04 gap. The components, and our read on each:

The honest conclusion: adjusted EPS overstates true owner earnings by roughly $1.00–1.50. The impairments are a two-year pattern (not one-offs), and intangible amortization, deal costs, and restructuring are the ongoing operating costs of a perpetual-acquisition strategy — adding them all back flatters the picture. A conservative owner-earnings EPS is closer to ~$14.50–15.00 for FY25 than the reported $16.00. The adjusted growth is real (gross profit nearly doubled); the adjusted level is somewhat generous.

A further GAAP wrinkle to ignore in trend analysis: the Q2 FY26 GAAP results include a ~$1,086.6M non-cash remeasurement gain on the OneOncology step-up to full ownership — a one-time GAAP benefit (correctly excluded from adjusted EPS) that, like the impairments, makes the GAAP series useless for run-rate.

Opioid liability

The remaining accrued opioid settlement liability is ~$4.3B (down from ~$4.9B), with cash payments of ~$416M/year through ~FY2038. This is a debt-like, FCF-reducing claim that is absent from net debt; any clean enterprise-value or FCF analysis must subtract it.

Working-capital float — the cash-flow caveat

Cencora runs a structurally negative cash-conversion cycle (~-12 days: DIO ~24, DSO ~29, DPO ~65) and net trade working capital of roughly -$9B (vs. -$4.5B in FY21). This is a powerful, low-cost financing source — but it is a one-directional float: it grows as revenue grows (more payables financing more inventory), and it reverses if revenue shrinks. Roughly $4.5B of the FY21→FY25 operating-cash-flow growth is payables float, not earnings. In a revenue contraction, OCF would temporarily fall below net income as the float unwinds. This is why adjusted FCF (~$3B FY25), not reported OCF (~$3.9B), is the right cash figure — and even that should be debited for the ~$416M/yr opioid cash.

Balance sheet and returns

Goodwill + intangibles total ~$22.5B against ~$3.4B of book equity, so tangible common equity is roughly -$19B — deeply negative, the legacy of acquisitions and buybacks. Consequently ROE (~107%) and P/B (~16x) are meaningless and should never be cited as quality signals; they are artifacts of a thin, negative-tangible equity base. The right lens is ROIC (genuinely high — light $668M capex, high-return incremental volume — though distorted upward by the negative working capital) and EV-based multiples. Net debt ~$10.2B post-OneOncology (~1.9x EBITDA), investment-grade.

Margins

The ~30bps of FY25 gross-margin expansion is mix-driven — RCA and the MSOs lift the blend above the ~2.7–3.0% core distribution rate — not core pricing power. Core distribution gross margin remains pressured by WAC deflation and low-margin GLP-1 volume; the segment margin improvement is the specialty/services overlay. This matters for valuation: the margin uplift is acquisition-bought, and its durability depends on the MSO bet holding.

Verdict (Financial Quality): Genuinely cash-generative and high-return on capital, but with a generous adjusted-earnings presentation and a float-flattered cash flow. Economics do improve with scale (incremental volume at high incremental ROIC, self-funding float), but the reported adjusted EPS is ~$1–1.5 rich, the cash flow embeds a reversible float, and the balance sheet carries ~$4.3B opioid + ~$1.8B physician-put claims outside headline debt. Use ROIC and EV/EBITDA; discard ROE, P/B, and the GAAP P/E.

8. Changes and Headwinds — Last Two Years

• Rebrand (Aug 2023): AmerisourceBergen → Cencora. Cosmetic, signaling the pivot beyond pure distribution.
• Leadership: Steven Collis → Bob Mauch as CEO (2024), Collis now Executive Chairman; CFO transition to Eva Boratto (eff. June 29, 2026), succeeding the retiring Jim Cleary. A bench in transition.
• The MSO build-out: RCA (Jan 2025), OneOncology to full ownership (Feb 2026), EyeSouth (announced). The defining strategic change of the period — and the source of doubled leverage.
• Portfolio pruning: MWI Animal Health being merged into Covetrus; U.S. hub consulting divested (Apr 30, 2026); residual PharmaLex/Profarma in the “Other” for-sale bucket.
• Walgreens ownership exit + PE acquisition: WBA fully exited its legacy ~26–28% ABC equity stake by Aug 2024 (relationship now purely commercial); Sycamore Partners (PE) acquired Walgreens Boots Alliance on Aug 28, 2025, raising the stakes on the 2029 contract renewals and a possible acceleration of ~1,200 WBA store closures.
• FY26 guidance reset (May 6, 2026): revenue cut to +4–6%, operating income raised to +12–14%, EPS to $17.65–$17.90 — the proximate cause of the ~25% drawdown.
• PharmaLex impairments: $418M (FY24) + $723.9M (FY25), fully writing off the 2023 acquisition.
• “Lawsuit trio” (mid-2026): a new California labor class action + the ongoing opioid liability + a 2024 data-breach settlement (~$40M), plus a ~$1M DOJ False Claims Act kickback settlement. None individually thesis-changing.
• Specialty wins: Kite (Gilead) CAR-T distribution support (June 2026); World Courier cell-and-gene contract momentum.

Verdict (Changes): Net neutral-to-slightly-negative for the thesis. The portfolio simplification and specialty wins are positives; the doubled leverage, the PharmaLex write-off, the Walgreens-under-PE overhang, and the growth deceleration are the offsetting negatives. The franchise is being actively reshaped — toward higher margin but higher risk.

9. Risk Analysis

Catastrophic-loss assessment: Low. This is an investment-grade, cash-generative, recession-resistant utility with settled (if still-paying) opioid exposure and diversified supply. The realistic downside is a de-rating and growth deceleration (risks 1–4 compounding), not impairment of capital. The tail risk that could genuinely break the franchise is risk #5 (a giant payer self-distributing), which remains low-probability given sub-1% distribution economics.

10. Valuation Discussion (Embedded Expectations)

No price target, no recommendation — this section frames what the market is underwriting and the scenario tree.

Where the multiple sits

At ~$281.5, Cencora trades at:

• ~15.8x forward adjusted EPS (FY26 midpoint ~$17.78)
• ~17.6x trailing adjusted EPS (FY25 $16.00)
• ~12.4x EV/EBITDA
• ~5.7% adjusted FCF yield (on ~$3B FY26E adj FCF / ~$54.8B mkt cap)
• Own-history percentiles (10yr): P/E ~63rd, EV-implied composite ~66th — moderately full vs its own past, despite the ~25% drawdown (which only retraced the multiple from the ~18–19x 2024–25 peak back toward its longer-run ~15–16x norm).

Embedded expectations

A Gordon-growth back-out on the ~5.7% FCF yield implies the market is pricing only ~2.8% perpetual FCF growth; the ~15.8x forward P/E implies only ~6–8% through-cycle EPS growth is needed to justify spot — well below management’s 10–14% algorithm. In other words, the tape is underwriting a meaningful deceleration from the historical ~14.7% adjusted-EPS compounding — pricing in a partial structural de-rating (IRA margin pressure, biosimilar disintermediation, the GLP-1 slowdown) but not a structural break. For the price to be expensive, you would need the bear case (Walgreens loss + Part-B biosimilar leakage + IRA fee erosion) to materialize together.

Scenario analysis (illustrative; no price target)

The skew is asymmetric to the upside from spot, precisely because the market already underwrites near-bear growth — the base case implies meaningful appreciation, the bull case substantial. The thing that makes this a HOLD rather than a pound-the-table long is that the bear case is a double compression (EPS growth and multiple de-rate together), and its triggers (Walgreens 2029, Part-B biosimilar leakage) are concentrated, binary, and not yet resolvable.

Sum-of-the-parts

A barbell SOTP — core distribution at ~10–12x EBITDA + higher-margin MSO/specialty (RCA/OneOncology/EyeSouth) at ~15–17x + International — blends to roughly $60–82B EV vs. ~$68B traded, i.e. directionally supportive but only partly crediting the specialty mix. Unlike CVS (whose SOTP lands ~22% below its traded EV), Cencora’s specialty slice is genuinely higher-quality and the parts math is supportive — but the redeemable-NCI leakage, ~$15B+ of impairment-prone goodwill, and the generous adjusted-earnings presentation rationally cap the credit. This is not a “hidden compounder trapped at a conglomerate discount”; it is a fairly-priced oligopolist with an optionality kicker on the MSO build-out.

Verdict (Valuation): Fairly-to-slightly-cheaply priced for a quality oligopolist, with the cheapest multiple in the Big-3 and a market underwriting sub-algorithm growth. The discount to McKesson is partly deserved; the ~25% drawdown over-corrects a revenue-optics miss but does not make the stock outright cheap on its own history.

11. Variant Perception

Consensus view: Sell-side is constructive — ~14 analysts, an average rating of ~4.18/5 (10 strong-buy), price targets clustered ~$350–356 (Barclays at $350 after a June-2026 cut, still Overweight). Short interest is low (~3% of float) — this is a consensus-long, lightly-shorted name, which means the contrarian risk is to downside surprises, not a squeeze. Consensus reads the FY26 revenue cut as margin-neutral optics and the MSO build as accretive.

Strongest bull case: A recession-proof oligopoly toll-road compounding adjusted EPS at the low-teens, trading at the cheapest multiple of the Big-3 and a ~5.7% FCF yield, with a higher-margin specialty/MSO growth engine the market under-credits. The revenue scare is noise (low-margin pass-through); operating income and EPS guidance went up. Biosimilars in Part B are a tailwind. Resumed buyback at a 25%-off price compounds per-share value. Re-rate toward McKesson and you have a mid-teens IRR.

Strongest bear case: A low-margin pass-through utility with ~25% revenue concentration in a PE-owned customer whose anchor contracts expire in 2029; structurally exposed to IRA list-price deflation and biosimilar disintermediation that will eventually leak from Part D mail into the high-margin Part B specialty pool; diversifying into physician practices at top-of-cycle 19x multiples with a fresh $1.14B impairment on its last big non-core bet; flattering earnings with generous add-backs and a reversible working-capital float; and decelerating to the low end of its own algorithm. The “cheap” multiple is a value trap that de-rates to ~12–13x as growth slows.

The 3–5 assumptions that matter most (the fulcrum):

1. Biosimilar economics — tailwind (Part B) vs. disintermediation (leaking into Part B). Most important.
2. Walgreens 2029 renewal — on stable economics, or lost/renegotiated under Sycamore.
3. IRA brand-fee margin — whether DSA renegotiation continues to “recoup the value” of list-price cuts.
4. MSO durability — does the roll-up integrate and compound, or follow PharmaLex into impairment?
5. Multiple regime — does the market keep paying ~15–16x, or de-rate the whole channel?

What would falsify each side: Bull falsified by (a) any indication of Part B biosimilar disintermediation, (b) a Walgreens loss/adverse renegotiation, or © a third year of MSO/acquisition impairment. Bear falsified by (a) a Walgreens renewal on stable terms through the mid-2030s, (b) continued operating-income growth at/above algorithm despite revenue deflation (proving the fee model holds), and © MSO segment margins expanding without write-offs.

12. Fact vs. Interpretation Table

13. Open Questions

1. Will Walgreens (under Sycamore) renew the 2029 distribution + WBAD contracts, and on what economics? The single highest-stakes unknown.
2. What is the split of brand fee-for-service vs. generic buy-and-hold gross profit — i.e., the true exposure of margin to IRA list-price deflation? Not disclosed.
3. Does biosimilar disintermediation stay confined to Part D mail, or leak into Part B specialty?
4. What multiples and management-fee margins do the MSOs actually earn, and will the ~$1.8B of physician puts be funded from cash flow or fresh debt?
5. Does adjusted FCF (~$3B) exclude the ~$416M/yr opioid cash? If so, true distributable FCF is lower.
6. How much of the FY26 EPS raise is the MWI held-for-sale depreciation suspension vs. genuine operating improvement?
7. What is the run-rate earnings split between Part B (physician-administered) and Part D businesses? Management declined to disclose.

14. What Must Be True

Bull case — what must be true

1. The fee model holds against deflation: operating income keeps growing 10–14% even as IRA cuts revenue — proving DSA renegotiation “recoups the value.”
2. Walgreens renews ~2029 on broadly stable economics (or the loss is offset by share gains elsewhere).
3. Biosimilars remain a net Part B tailwind, not a disintermediation threat that reaches specialty.
4. The MSO roll-up compounds without further impairment, justifying the 19x prices and doubled leverage.
5. The multiple holds ~15–16x or re-rates toward McKesson.

Bull falsification test: Operating-income growth falling below ~7% while revenue also deflates (fee model breaking), or a confirmed Walgreens loss/adverse renegotiation, or a third consecutive year of MSO/acquisition impairment. Any one breaks the bull.

Bear case — what must be true

1. Disintermediation reaches Part B, or Walgreens is lost/renegotiated down at 2029.
2. IRA fee compression outpaces DSA renegotiation, eroding dollar margin.
3. MSO bets impair (PharmaLex pattern repeats), and the ~$1.8B physician puts drain cash.
4. Growth decelerates to mid-single-digits and the channel de-rates to ~12–13x.

Bear falsification test: A Walgreens renewal on stable terms through the mid-2030s, plus continued operating-income growth at/above algorithm despite revenue deflation, plus MSO segment margin expansion without write-offs over the next 2–3 years. That combination invalidates the value-trap thesis.

15. Source Appendix

Primary sources relied upon:

• Cencora FY2025 Form 10-K (filed 2025-11-25) and FY2021–FY2024 10-Ks; Q2 FY2026 Form 10-Q (filed 2026-05-06) and prior 10-Qs.
• Cencora Q2 FY2026 earnings call transcript (May 6, 2026) and prior earnings/conference transcripts.
• Cencora DEF 14A proxy statements (2025, 2026) for incentive metrics and compensation.
• Cencora Form 8-K filings, incl. the May 29, 2026 CFO-transition 8-K (Item 5.02).
• Form 3/4/5 insider-transaction record (EDGAR).
• SEC EDGAR XBRL financial data, reconciled to filings.
• McKesson (MCK) and Cardinal Health (CAH) public filings and consensus for peer comps.
• Industry: Healthcare Distribution Alliance value-add data; IQVIA volume data; public reporting on the Inflation Reduction Act, biosimilar conversion, GLP-1 dynamics, and the Sycamore/Walgreens acquisition.

The body of this article carries no investment recommendation and no price target; valuation is discussed solely as embedded expectations and scenario analysis. The sole exception is the labeled “Claude’s Take” block at the top, which is the author’s own independent opinion.

APPENDIX A — Standard Diligence Questionnaire

Cencora, Inc. (NYSE: COR) — Standard Diligence Questionnaire

Supplemental diligence questionnaire. Fact/Interpretation/Assumption labeled where it matters.

General

What thoughtful questions have other investors asked about this company? The recurring sell-side questions (Q2 FY26 call, May 2026) cluster on: (1) whether the FY26 revenue-guidance cut signals a structural slowdown in operating-income growth (Caliendo/UBS pressed this — core OI growth fell to ~7%, the low end of the algorithm); (2) the long-term impact of brand→biosimilar conversion, and specifically whether disintermediation leaks from low-margin Part D mail into high-margin Part B specialty (Santangelo/Barclays); (3) the apportionment of earnings between Part B (physician-administered) and Part D businesses — which management declined to disclose (Hill/Deutsche Bank); (4) how distributor dollar-margin survives GLP-1 list-price cuts coming 1/1/2027 (Percher/Nephron); and (5) the cadence and magnitude of resumed buybacks vs. continued MSO M&A (Wright/Morgan Stanley).

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Neither, really — drug distribution is non-cyclical (recession-proof, demand-inelastic). Earnings are at an all-time high in absolute terms (adjusted EPS compounding ~14.7%/yr) but the growth rate is decelerating to the low end of the algorithm. The cyclical variable that exists is the specialty/biotech funding environment (affects World Courier) and GLP-1 demand — both recently softening modestly.

Driven by external environment or internal actions? Predominantly internal — specialty mix shift, generic sourcing, M&A (RCA/OneOncology), buyback. External drivers (volume growth, GLP-1, IRA deflation) are secondary. Interpretation.

How stable are revenues? The volume is extremely stable (repeat-purchase necessities, auto-replenishment). The reported dollar revenue is volatile in a misleading way — it is a pass-through gross figure whipped around by drug list prices (IRA WAC cuts), GLP-1 mix, and biosimilar conversion, none of which proportionally affect profit.

Outlook for products/services? Structurally positive volume (aging demographics, chronic disease, specialty/biologic pipeline). Mid-single-digit US script-volume growth + specialty value-per-script uplift.

How big is the market — growing/shrinking, domestic/international? US drug distribution intermediates $500B+ of flow, growing mid-single-digits; ~91% of COR revenue is U.S., ~9% international (Europe via Alliance Healthcare, plus Brazil). Growing, primarily domestic.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable — a decade-old three-firm oligopoly (MCK/COR/CAH ~90%+ share) with no share volatility. Competitive intensity is constant; the marginal threats are channel shifts (Amazon, DTC, payer in-sourcing), not new distributors.

How profitable is the business (ROIC, ROE)? ROE (~107%) and P/B (~16x) are meaningless — tangible equity is roughly -$19B (goodwill+intangibles ~$22.5B vs. ~$3.4B book equity). The honest metric is ROIC, genuinely high (~12–22% depending on method, vs. ~7–9% WACC) on ~0.2%-of-sales capex and a negative-working-capital float — but the float distorts it upward. Fact + Interpretation.

How profitable is the industry — competitors, barriers to entry? Razor-thin (sub-1% operating margin) but high-barrier. The thinness is the barrier: no profit umbrella under which a sub-scale entrant could undercut. Three competitors, share-stable.

Can the business be easily understood? Yes at the model level (toll-road on drug flow), but the GAAP-vs-adjusted bridge, MSO purchase accounting, redeemable NCIs, and float-flattered cash flow make the financials genuinely complex.

Undermined by foreign low-cost labor? No — it is a domestic physical-logistics + regulatory-compliance network; not offshorable.

Do brands matter? Modestly — Good Neighbor Pharmacy/Elevate (independent-pharmacy networks) and World Courier carry brand value; core distribution is a B2B utility where service reliability, not brand, wins.

Nature of competition? Service reliability, generic-sourcing scale, technology integration, contract economics, specialty breadth — periodic high-stakes contract renegotiations with giant customers (Walgreens).

Customers’ switching costs? Real but not absolute — deep operational integration (auto-replenishment, ordering systems, sole-supplier status) makes switching disruptive, but the largest customers have the scale to renegotiate hard or threaten to switch (as Walgreens has historically).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The negative-working-capital float (~-$9B) is an off-balance-sheet financing benefit. Generic-sourcing relationships and the WBAD JV are valuable but unbooked. Interpretation.

Off-balance-sheet / debt-like liabilities? Yes, and material: (1) opioid settlement ~$4.3B (~$416M/yr to ~2038), (2) ~$1.8B redeemable physician-put/earn-out claims (RCA/OneOncology), both outside headline net debt. Add both to any honest EV. Fact.

How conservative is the accounting? Mixed-to-aggressive on presentation. Adjusted EPS adds back recurring impairments, perpetual deal-amortization, and ongoing integration/restructuring costs — overstating owner earnings by ~$1.00–1.50. The float flatters operating cash flow. Revenue uses the legacy Revenues tag. Two consecutive years of goodwill impairment (PharmaLex) indicate M&A overpayment. Interpretation.

How CapEx-hungry? Among the least in large-cap industrials — ~0.2% of sales (~$668M on $321B). Asset-light.

Capital Allocation & Management

How much FCF, and how is it used? ~$3B adjusted FCF (FY26E). Uses, in priority: (1) M&A (MSO roll-up — the dominant recent use), (2) debt paydown ($1.3B term loans FY26), (3) resumed buyback (~$1B by end-CY26), (4) a small growing dividend (~14% payout). Philosophy: “balanced capital deployment” with genuine ROIC/FCF incentive metrics.

Significant acquisitions recently? Yes — RCA (~$5.7B, Jan 2025), OneOncology (full ownership, ~$7.39B EV, Feb 2026, put at 19x EBITDA), EyeSouth (announced); earlier Alliance Healthcare (2021) and the fully-impaired PharmaLex (2023). A serial acquirer testing its discipline at top-of-cycle MSO prices. Fact + Interpretation.

Buying back shares? Yes — ~7.5% net share reduction FY22→FY25, paused FY25 for M&A, resuming ~$1B. Timing: heaviest at the FY24 run-up, paused at the peak, resuming lower — mixed discipline (the pause was cash-forced).

Issuing large amounts of new shares to insiders? No material dilution; SBC is modest for the sector.

Compensation policy / incentive alignment? A genuine positive: STI = 40% Adj OI / 25% Adj EPS / 25% Adj FCF / 10% other; LTI PSUs = 75% Adj EPS CAGR + 25% Adj ROIC + TSR modifier. Real capital-discipline metrics — though all on an adjusted basis that adds back M&A-created charges. CEO Mauch FY25 comp ~$18.3M. Fact.

Motivations of management? A leadership bench in transition (CEO Mauch ~2 yrs; new CFO Eva Boratto, ex-CVS CFO, eff. June 2026; Collis as Exec Chair). The ROIC/FCF metric set suggests value-creation orientation, but the MSO empire-building risk is real and must be monitored.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary US common stock, NYSE.

Dividend policy? Small and growing (~$2.20–2.40/yr, ~0.9% yield, ~14% payout) within the EPS-growth algorithm. Not a Dividend Aristocrat; a token return.

How profitable? Thin on sales (sub-1% operating margin), high on capital (ROIC well above WACC). The right framing is gross-profit dollars and ROIC, not margins.

Net income diverging from cash from operations? Historically OCF > net income (the float). But the divergence is the caveat: ~$4.5B of FY21–25 OCF growth is reversible payables float, not earnings. In a revenue contraction OCF would temporarily fall below net income. Interpretation. Adjusted FCF (~$3B) is the cleaner figure.

Risks & Downside

What would cause the stock to decline? A Walgreens 2029 loss/renegotiation; evidence of Part B biosimilar disintermediation; IRA fee compression outpacing DSA renegotiation; further MSO impairment; payer self-distribution; or simply a channel-wide multiple de-rate as growth decelerates (the “double compression” bear).

Risk of catastrophic loss? Low. Investment-grade, recession-proof, diversified supply, settled (if still-paying) opioid exposure. The realistic downside is de-rating + deceleration, not capital impairment.

Chance of total loss? Negligible. The only path is the low-probability tail of a giant payer self-distributing and collapsing the oligopoly — economically unjustified at sub-1% distribution margins.

Recent News & Events

Has the business environment changed recently? Yes, at the margin: FY26 revenue guide cut (May 2026) on slower GLP-1s + faster biosimilar conversion + IRA deflation; OneOncology brought to full ownership (Feb 2026); MWI being merged into Covetrus; Sycamore (PE) acquired Walgreens (Aug 2025), raising 2029-renewal stakes; CFO transition to Eva Boratto.

Significant acquisitions? OneOncology (Feb 2026), EyeSouth (announced) — see above.

Change in accounting policies? New three-unit reporting structure from Q1 FY26 (carving “Other”/divestiture candidates out); MWI reclassified to held-for-sale (suspending depreciation, a one-time EPS benefit).

Recent changes — new markets, facilities, management? Leadership transition (CEO Mauch 2024, CFO Boratto 2026); portfolio pruning toward US specialty + MSOs; specialty wins (Kite CAR-T distribution, June 2026; World Courier cell-and-gene momentum).

APPENDIX B — Source Appendix

Cencora, Inc. (NYSE: COR) — Source Appendix

Primary sources first. Accessed June 12, 2026 unless noted. Internal/Drive items labeled.

Company SEC filings (primary)

1. Cencora FY2025 Form 10-K (filed 2025-11-25, for fiscal year ended 2025-09-30). CIK 0001140859. Business description, segment data (Note 13), customer concentration (Walgreens+Boots ~25% rev / ~38% A/R; Evernorth ~13%), WBAD/Walgreens contract terms (to 2029/2031), Sycamore/WBA risk factor, opioid liability, goodwill impairment ($723.9M), MD&A revenue/GP/OI bridges. EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001140859
2. Cencora FY2021–FY2024 Forms 10-K (abc-20210930, abc-20220930, cor-20230930, cor-20240930). Multi-year revenue, NI, op income, gross profit, buyback, opioid accrual history; PharmaLex FY24 impairment ($418M).
3. Cencora Q2 FY2026 Form 10-Q (filed 2026-05-06, quarter ended 2026-03-31). OneOncology consolidation, debt step-up (~$12.39B total debt), $1,086.6M remeasurement gain, redeemable-NCI/contingent-consideration balances, three-unit segment note.
4. Cencora Forms 10-Q FY2024–FY2026 (cor-20240331, -20240630, -20250331, -20250630, -20251231, -20260331).
5. Cencora Form 8-K, 2026-05-29 (Item 5.02) — CFO transition: Eva C. Boratto appointed CFO effective 2026-06-29, succeeding the retiring James Cleary.
6. Cencora Form 8-K earnings exhibits — Q2 FY2026 (2026-05-06) and prior, for non-GAAP reconciliations and adjusted-EPS guidance ($17.65–$17.90).
7. Cencora DEF 14A proxy statements (2025, 2026) — executive compensation; STI metrics (40% Adj OI / 25% Adj EPS / 25% Adj FCF / 10%); LTI PSU metrics (75% Adj EPS CAGR + 25% Adj ROIC + TSR modifier); CEO Mauch FY25 comp ~$18.3M; security-ownership table.
8. Cencora Forms 3/4/5 (EDGAR insider-transaction record, 2024–2026) — including director Dermot Mark Durcan open-market purchase (~4,000 sh @ ~$266.26, ~2026-05-28); routine officer 10b5-1 activity.

Earnings call & event transcripts (primary)

9. Cencora Q2 FY2026 earnings call (2026-05-06) — revenue guidance cut to +4–6%, OI raised to +12–14%, adj EPS $4.75 (+7.5%); GLP-1/biosimilar/IRA commentary; CFO retirement; resumed $1B buyback. (company earnings webcast/transcript)
10. Cencora Q1 FY2026 (2026-02-04), Q4 FY2025 (2025-11-05), and prior earnings calls (company earnings webcasts/transcripts); conference presentations (J.P. Morgan, Barclays, BofA, Leerink, Morgan Stanley healthcare conferences, 2024–2026).

Quantitative data sources

11. SEC EDGAR XBRL company facts (SEC EDGAR company facts API) — revenue (legacy Revenues tag), NetIncomeLoss, OperatingIncomeLoss, GrossProfit, OCF, capex, buybacks, equity, debt. Reconciled to 10-K.
12. Market-data provider fundamentals & own-history valuation percentiles — snapshot (price ~$281.5, mkt cap, EV, EBITDA, ROE, margins, short interest), own-history valuation percentiles (P/E 63rd, P/S 83rd, composite 66th).
13. Financial news aggregation — Barclays PT cut to $350 (2026-06-10, Overweight); Kite CAR-T distribution support (2026-06-02); CFO/buyback/“lawsuit trio” (2026-06-01); CFO 8-K (2026-05-29).
14. Public market-data feeds — price, market cap, EV, debt, peer multiples (reconciled to filings/consensus where used).

Peer & industry sources

15. McKesson (MCK) and Cardinal Health (CAH) public filings and consensus — Big-3 peer comp table (forward P/E, EV/EBITDA, ROIC, leverage).
16. Healthcare Distribution Alliance — channel value-add data (~$78–80B/yr).
17. IQVIA — US prescription-volume growth data.
18. Public reporting (Reuters, Bloomberg, Healthcare Dive, company press releases) on: the Inflation Reduction Act and Medicare drug-price negotiation; GLP-1 demand and 1/1/2027 price dynamics; brand→biosimilar conversion economics; the Sycamore Partners acquisition of Walgreens Boots Alliance (closed 2025-08-28); WBA’s progressive exit of its legacy ABC equity stake (2023–2024).

Analytical frameworks

19. Greenwald & Kahn, Competition Demystified (moat taxonomy: economies of scale + customer captivity; ROIC/share-stability tests) and Chancellor/Marathon, Capital Returns (capital-cycle lens applied to the MSO roll-up).

Note: sell-side price targets (e.g., Barclays $350; consensus ~$356) and third-party analyst targets are cited as market color only and are explicitly NOT used as a price target in this article.